UBROLEXIN INTRAMAMMARY SUSPENSION FOR LACTATING DAIRY COWS 10G

Uses Treatment of clinical mastitis in lactating dairy cows for bacteria susceptible to the combination of cefalexin and kanamycin such as Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis and Escherichia coli. Dosage and administration For intramammary use. Treat the infected quarter(s) twice, leaving an interval of 24 hours between treatments. Use the contents of one syringe (containing 200 mg cefalexin as monohydrate and 100,000 I.U. kanamycin as monosulphate) per quarter per treatment. Each syringe is for single use only. Before infusion, the udder should be milked out completely, the teat should be thoroughly cleaned and disinfected and care should be taken to avoid contamination of the injector nozzle. Contra-indications, warnings, etc Do not use in lactating dairy cows with a known hypersensitivity to cefalexin and/or kanamycin. Do not use in non-lactating cattle. Do not use in the case of known resistance of cefalexin and/or kanamycin. In general, combination with bacteriostatic antimicrobials should be avoided. In case of resistance to cefalexin, cross-resistance with other cephalosporins is likely to occur. In case of resistance to kanamycin, cross-resistance occurs between kanamycin, neomycin and paromomycin. A one way resistance with streptomycin is known. Special precautions for use in animals: The product should be used for treatment of clinical mastitis only. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional and farm level) epidemiological information about susceptibility of the target bacteria as well as by taking into account official national antimicrobial policies. Inappropriate use of the product may increase the prevalence of bacteria resistant to cefalexin and kanamycin and may decrease the effectiveness of treatment with other cephalosporins or aminoglycosides due to the potential for cross-resistance. Studies in laboratory animals have not produced any evidence of teratogenic effect. Field studies in dairy cows have not produced any evidence of a teratogenic, foetotoxic or maternotoxic effect. The product can be used in pregnant cows. The product is intended for use during lactation. Special precautions for the user: